Brainomix Wins Prestigious Award for Innovative Stroke Technology at International Competition

Brainomix Triumphs in Global Health Tech Space

In a remarkable achievement, Brainomix, an innovator in AI imaging tools for stroke and lung fibrosis, was recently awarded top honors at the American Heart Association's Health Tech Competition during the 2025 Scientific Sessions in New Orleans. This recognition highlights the company's commitment to transforming the landscape of cardiovascular healthcare and improving patient outcomes, particularly in the realm of stroke recovery.

Held live at the prestigious event, the Health Tech Competition serves as a platform for healthcare innovators to showcase their digital solutions aimed at preventing and treating various cardiovascular diseases, including strokes. A panel comprising experts from both scientific and business backgrounds evaluates the submissions based on their validity, scientific rigor, and potential impact on patient care. Brainomix's innovative Brainomix 360 Stroke technology excelled in these criteria, winning the award in the Science category.

Committed to Patient Outcomes

Dr. Michalis Papadakis, the CEO and co-founder of Brainomix, expressed pride in receiving such an esteemed accolade from the American Heart Association. He stated, “We’re honored to be recognized for our Brainomix 360 Stroke technology. This award affirms our commitment to transforming cardiovascular and stroke care through innovation and scientific rigor.”

By joining the American Heart Association’s Center for Health Technology Innovation Innovators' Network, Brainomix is now connected with a consortium of entrepreneurs, researchers, and health providers. This network aims to leverage collaborative efforts to propel advancements in cardiovascular and brain health innovation.

Pioneering AI in Healthcare

Starting as a spin-out from the University of Oxford, Brainomix focuses on developing cutting-edge AI-powered tools that assist clinicians in making swift and accurate treatment decisions for stroke patients. The Brainomix 360 Stroke technology stands out as the world's first fully automated AI-imaging platform designed to perform comprehensive acute stroke assessments throughout the patient pathway. This enables healthcare professionals to make more informed treatment and transfer decisions, ultimately reducing disability and potentially saving lives.

Additionally, the company’s Brainomix 360 e-Lung technology utilizes AI-driven CT biomarkers to monitor and predict disease progression in pulmonary fibrosis, representing another significant leap in medical imaging technology.

Global Impact and Recognition

Having established its presence in over 20 countries, Brainomix continues to expand its influence in AI medical imaging. Their dedication to precision medicine and improved healthcare delivery has positioned them as leaders in the health tech industry. The company operates offices in the UK, Ireland, and the USA, where they are consistently working to innovate and enhance the capabilities of medical imaging.

With this recent honor from the American Heart Association, Brainomix is not just celebrating a victory; they are reinforcing their mission to advance global health through innovative technology. The Health Tech Competition has proven to be an influential stage for nurturing innovation in healthcare, aligning perfectly with Brainomix’s vision of delivering exceptional solutions in the medical field.

To discover more about Brainomix's groundbreaking technology and ongoing projects, visit their official website at www.brainomix.com and follow them on social media platforms including Twitter, LinkedIn, and Facebook. Their journey in revolutionizing stroke and pulmonary fibrosis care is one to watch as they continue to make strides in healthcare innovation.